VANCOUVER, British Columbia--(BUSINESS WIRE)-- ProtoKinetix (OTCBB: PKTX) (http://www.protokinetix.com), a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP™) for medicine, biotechnology and cosmetic industries today announced that the Company has completed the funding requirements for trials to test the effectiveness of their AAGP™ molecule’s anti-inflammatory properties.
This course of action is a follow up to the many previous results showing that AAGP™ has the ability to provide a layer of protection against the inflammation of cells. The inflammation of pancreatic islet cells is widely recognized as the root cause of diabetes. Inflammation is, in general present in many diseases and disorders including atherosclerosis, arthritis, and asthma.
“We expect these confirmatory trials will clearly indicate just how effective the AAGP™ molecule is against a host of inflammatory conditions,” said Ross L. Senior, CEO of ProtoKinetix.
ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP™) for medicine and the biotechnology and cosmetic industries. PKTX’s primary focus is on the therapeutic potential for AAGP™ in the treatment of Diabetes, inflammatory diseases, skin protection and anti-aging.
Ross L. Senior – President and CEO
Ross L. Senior, President and CEO
KEYWORDS: United States North America Canada New York
INDUSTRY KEYWORDS: Technology Nanotechnology Health Biotechnology Public Policy/Government Healthcare Reform Research Diabetes Science General Health